Lenabdor (Lenalidomide)

Lenalidomide binds to the cereblon component of an E3 ubiquitin ligase complex, altering the degradation of specific transcription factors. This leads to reduced cytokine production, inhibition of new blood‑vessel formation, and programmed cell death of malignant plasma and lymphoid cells, providing its antineoplastic effect.

The dosage of Lenabdor is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Prescribers determine the appropriate strength, schedule, and duration according to clinical guidelines and patient needs.

Lenabdor is classified as pregnancy category X because it can cause severe fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both the patient and partner. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To request Lenabdor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenabdor belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It provides oral administration, anti‑angiogenic activity, and the ability to enhance immune‑mediated tumor clearance, making it a valuable option in combination regimens for relapsed or refractory multiple myeloma.

Lenabdor should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lenabdor is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water, and the dosing schedule (e.g., daily or on specific days of a cycle) is determined by the treating physician.

The most serious risks include severe neutropenia or leukopenia that can lead to life‑threatening infections, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, and the potential for secondary primary malignancies. Patients should be monitored closely for signs of infection, clotting, and new cancer development.

Lenabdor should not be used by individuals who are pregnant, planning to become pregnant, or not using reliable contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation, and in those receiving other teratogenic agents.